The henipaviruses, represented by Hendra (HeV) and Nipah (NiV) viruses are highly pathogenic zoonotic paramyxoviruses with uniquely broad host tropisms responsible for repeated outbreaks in Australia, Southeast Asia, India and Bangladesh. The high morbidity and mortality rates associated with infection and lack of licensed antiviral therapies make the henipaviruses a potential biological threat to humans and livestock. Henipavirus entry is initiated by the attachment of the G envelope glycoprotein to host cell membrane receptors. Previously, henipavirus-neutralizing human monoclonal antibodies (hmAb) have been isolated using the HeV-G glycoprotein and a human na？ve antibody library. One cross-reactive and receptor-blocking hmAb (m102.4) was recently demonstrated to be an effective post-exposure therapy in two animal models of NiV and HeV infection, has been used in several people on a compassionate use basis, and is currently in development for use in humans. Here, we report the crystal structure of the complex of HeV-G with m102.3, an m102.4 derivative, and describe NiV and HeV escape mutants. This structure provides detailed insight into the mechanism of HeV and NiV neutralization by m102.4, and serves as a blueprint for further optimization of m102.4 as a therapeutic agent and for the development of entry inhibitors and vaccines.
References
[1]
Eaton BT, Broder CC, Middleton D, Wang LF (2006) Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 4: 23–35. doi: 10.1038/nrmicro1323
[2]
Eaton BT, Mackenzie JS, Wang L-F (2007) Henipaviruses. In: Knipe DM, Howley PM, editors. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins. pp. 1587–1600.
[3]
Field H, Young P, Yob JM, Mills J, Hall L, et al. (2001) The natural history of Hendra and Nipah viruses. Microbes Infect 3: 307–314. doi: 10.1016/s1286-4579(01)01384-3
[4]
Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, et al. (1995) Infection of humans and horses by a newly described morbillivirus. Med J Aust 162: 642–645.
[5]
Playford EG, McCall B, Smith G, Slinko V, Allen G, et al. (2010) Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis 16: 219–223. doi: 10.3201/eid1602.090552
[6]
Wong KT, Robertson T, Ong BB, Chong JW, Yaiw KC, et al. (2009) Human Hendra virus infection causes acute and relapsing encephalitis. Neuropathol Appl Neurobiol 35: 296–305. doi: 10.1111/j.1365-2990.2008.00991.x
[7]
Bishop KA, Broder CC (2008) Hendra and Nipah: Lethal Zoonotic Paramyxoviruses. In: Scheld WM, Hammer SM, Hughes JM, editors. Emerging Infections. Washington, D.C.: American Society for Microbiology. pp. 155–187.
Xu K, Chan YP, Rajashankar KR, Khetawat D, Yan L, et al. (2012) New insights into the hendra virus attachment and entry process from structures of the virus g glycoprotein and its complex with ephrin-b2. PLoS One 7: e48742. doi: 10.1371/journal.pone.0048742
[10]
Homaira N, Rahman M, Hossain MJ, Epstein JH, Sultana R, et al. (2010) Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect 138: 1630–1636. doi: 10.1017/s0950268810000695
[11]
Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, et al. (2011) Date Palm Sap Linked to Nipah Virus Outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis 12: 65–72. doi: 10.1089/vbz.2011.0656
[12]
Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, et al. (2007) Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 13: 1031–1037. doi: 10.3201/eid1307.061128
[13]
Luby SP, Hossain MJ, Gurley ES, Ahmed BN, Banu S, et al. (2009) Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001–2007. Emerg Infect Dis 15: 1229–1235. doi: 10.3201/eid1508.081237
[14]
Anonymous (2012) Nipah encephalitis, human - Bangladesh: (Jipurhat). International Society for Infectious Diseases archive no. 20120212.1040138 20120212.1040138.
[15]
Lee B, Ataman ZA (2011) Modes of paramyxovirus fusion: a Henipavirus perspective. Trends Microbiol 19: 389–399. doi: 10.1016/j.tim.2011.03.005
[16]
Dutch RE (2010) Entry and Fusion of Emerging Paramyxoviruses. PLoS Pathog 6: e1000881. doi: 10.1371/journal.ppat.1000881
Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, et al. (2006) Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 80: 891–899. doi: 10.1128/jvi.80.2.891-899.2006
[19]
Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, et al. (2008) Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis 197: 846–853. doi: 10.1086/528801
[20]
Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, et al. (2009) A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 5: e1000642. doi: 10.1371/journal.ppat.1000642
[21]
Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, et al. (2011) A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 3: 105ra103. doi: 10.1126/scitranslmed.3002901
[22]
Rockx B, Bossart KN, Feldmann F, Geisbert JB, Hickey AC, et al. (2010) A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol 84: 9831–9839. doi: 10.1128/jvi.01163-10
[23]
Xu K, Rajashankar KR, Chan YP, Himanen JP, Broder CC, et al. (2008) Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A 105: 9953–8. doi: 10.1073/pnas.0804797105
[24]
Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489: 526–532. doi: 10.1038/nature11414
[25]
Julien JP, Lee PS, Wilson IA (2012) Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev 250: 180–198. doi: 10.1111/imr.12005
[26]
Kwong PD, Mascola JR (2012) Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. Immunity 37: 412–425. doi: 10.1016/j.immuni.2012.08.012
[27]
Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, et al. (2006) Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 281: 34610–34616. doi: 10.1074/jbc.m603275200
[28]
Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, et al. (2006) Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 281: 15829–15836. doi: 10.1074/jbc.m600697200
[29]
Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, et al. (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108: 14216–14221. doi: 10.1073/pnas.1111497108
[30]
Changela A, Wu X, Yang Y, Zhang B, Zhu J, et al. (2011) Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 85: 2524–2535. doi: 10.1128/jvi.02335-10
[31]
Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098–8110. doi: 10.1128/jvi.00966-10
[32]
Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107: 11483–11488. doi: 10.1073/pnas.1004600107
[33]
Broder CC (2010) Therapeutics and Vaccines against Hendra and Nipah Viruses. In: Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R, editors. New Generation Vaccines. New York: Informa Healthcare USA. pp. 885–894.
[34]
Broder CC (2012) Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol 2: 176–187. doi: 10.1016/j.coviro.2012.02.016
[35]
Anonymous (2010) Hendra virus, equine - Australia (04): (Queensland) human exposure. International Society for Infectious Diseases archive no. 20100522.1724 20100522.1724.
[36]
Bowden TA, Aricescu AR, Gilbert RJ, Grimes JM, Jones EY, et al. (2008) Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nat Struct Mol Biol 15: 567–572. doi: 10.1038/nsmb.1435
[37]
Bowden TA, Crispin M, Harvey DJ, Aricescu AR, Grimes JM, et al. (2008) Crystal Structure and Carbohydrate Analysis of Nipah Virus Attachment Glycoprotein: A Template for Antiviral and Vaccine Design. J Virol 82: 11628–11636. doi: 10.1128/jvi.01344-08
[38]
Bowden TA, Crispin M, Harvey DJ, Jones EY, Stuart DI (2010) Dimeric architecture of the Hendra virus attachment glycoprotein: evidence for a conserved mode of assembly. J Virol 84: 6208–6217. doi: 10.1128/jvi.00317-10
[39]
Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ (2010) A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 16: 46–58.
